Evidence map›Paper›PMID 36680114›Full record

ArticleViruses2022

Structural Investigations on Novel Non-Nucleoside Inhibitors of Human Norovirus Polymerase.

Gilda Giancotti, Giulio Nannetti, Gilda Padalino, Martina Landini, Nanci Santos-Ferreira, Jana Van Dycke, Valentina Naccarato, Usheer Patel, Romano Silvestri, Johan Neyts and 6 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 5 countries.

Gilda GiancottiSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.ORCID 0000-0002-6326-069X
Giulio NannettiMedical School, Faculty of Medicine, Health and Life Science, Swansea University, Swansea SA2 8PP, UK.ORCID 0000-0003-3227-1537
Gilda PadalinoSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Martina LandiniSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Nanci Santos-FerreiraKU Leuven-Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium.ORCID 0000-0003-4995-5580
Jana Van DyckeKU Leuven-Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium.ORCID 0000-0003-1632-3499
Valentina NaccaratoDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Usheer PatelSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Romano SilvestriDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-2489-0178
Johan NeytsKU Leuven-Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium.ORCID 0000-0002-0033-7514
Roberto Gozalbo-RoviraDepartment of Microbiology, School of Medicine, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0003-3427-3800
Jésus Rodríguez-DíazDepartment of Microbiology, School of Medicine, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-9698-7684
Joana Rocha-PereiraKU Leuven-Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium.ORCID 0000-0001-8299-3787
Andrea BrancaleSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.ORCID 0000-0002-9728-3419
Salvatore FerlaMedical School, Faculty of Medicine, Health and Life Science, Swansea University, Swansea SA2 8PP, UK.ORCID 0000-0002-5918-9237
Marcella BassettoDepartment of Chemistry, College of Science and Engineering, Swansea University, Swansea SA2 8PP, UK.ORCID 0000-0002-2491-5868
Cardiff University · GBRega Institute for Medical Research · BESwansea University · GBSapienza University of Rome · ITUniversitat de València · ES

Funding

Wellcome Trust
6 · The paper itself

Abstract

Human norovirus is the first cause of foodborne disease worldwide, leading to extensive outbreaks of acute gastroenteritis, and causing around 200,000 children to die annually in developing countries. No specific vaccines or antiviral agents are currently available, with therapeutic options limited to supportive care to prevent dehydration. The infection can become severe and lead to life-threatening complications in young children, the elderly and immunocompromised individuals, leading to a clear need for antiviral agents, to be used as treatments and as prophylactic measures in case of outbreaks. Due to the key role played by the viral RNA-dependent RNA polymerase (RdRp) in the virus life cycle, this enzyme is a promising target for antiviral drug discovery. In previous studies, following in silico investigations, we identified different small-molecule inhibitors of this enzyme. In this study, we rationally modified five identified scaffolds, to further explore structure-activity relationships, and to enhance binding to the RdRp. The newly designed compounds were synthesized according to multiple-step synthetic routes and evaluated for their inhibition of the enzyme in vitro. New inhibitors with low micromolar inhibitory activity of the RdRp were identified, which provide a promising basis for further hit-to-lead optimization.

Indexed as

Antiviral AgentsEnzyme InhibitorsNorovirusHumansRNA-Dependent RNA PolymeraseAntiviral AgentsEnzyme InhibitorsRNA-Dependent RNA Polymerasecomputer-aided drug designhuman norovirusRdRp inhibitors

Identifiers

PMID36680114
PMCPMC9864251
OpenAlexW4313414900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.